The FDA’s drug approval system runs on two foundational submission types, and confusing them costs development programmes time, capital, and regulatory credibility. An IND (Investigational New Drug application) and an NDA (New Drug Application) are not variations on the same theme. They govern entirely different stages of a drug’s life, carry different data burdens, and produce different legal permissions. If your programme is approaching first-in-human trials or preparing for a regulatory strategy conversation with investors, understanding this distinction precisely is non-negotiable.
Quick Answer
An IND authorises a sponsor to administer an investigational drug to human subjects in clinical trials. An NDA requests FDA permission to market that drug commercially. The IND comes first, opens the door to clinical investigation, and the NDA closes the loop by converting clinical evidence into a commercial licence. One is a permission to test; the other is a request to sell.
What the IND and NDA Actually Represent
The IND and NDA sit at opposite ends of a single regulatory arc. The IND, governed by 21 CFR Part 312, is the entry point. It authorises a sponsor to ship an investigational compound across state lines and administer it to human subjects. Without an active IND, clinical trials in the United States cannot legally proceed.
The NDA, governed by 21 CFR Part 314, is the exit point. It’s the formal request for FDA permission to market a new drug, and it requires the sponsor to demonstrate substantial evidence of safety and efficacy drawn from adequate and well-controlled clinical trials. Think of the IND as opening a door and the NDA as walking through a completely different one, carrying years of accumulated evidence.
Three IND Types Worth Knowing
The FDA recognises three IND categories, and which one applies to your programme shapes your filing requirements significantly.
- Commercial IND: Filed by a sponsor intending to eventually market the drug. This is the standard route for biotech companies and pharmaceutical developers.
- Investigator IND: Filed by an individual researcher, typically at an academic institution, who both sponsors and conducts the trial. Common for investigator-initiated studies exploring off-label or repurposing applications.
- Emergency IND: Authorises use of an investigational drug in a life-threatening situation when no alternatives exist and there is no time for standard IND submission.
The distinction between commercial and investigator INDs matters for early-stage biotech founders who may be spinning out of academic research. If your programme began as an investigator IND, you’ll need to assess whether to transfer sponsorship before scaling toward a commercial NDA pathway.
The 30-Day Clock
After IND submission, the FDA has 30 days to place a clinical hold. Silence constitutes implicit approval to proceed. This is faster than most first-time founders expect, and it creates a specific planning obligation: your pre-IND meeting with FDA should resolve any anticipated chemistry, manufacturing, and controls (CMC) or preclinical concerns before that clock starts.
What an NDA Actually Demands
An NDA is the most data-intensive submission in drug development. It must contain everything the FDA needs to evaluate whether a drug is safe and effective for its proposed indication, whether it can be manufactured consistently at commercial scale, and whether the proposed labelling accurately reflects the benefit-risk profile.
NDA submissions follow the Common Technical Document (CTD) structure, a five-module format used internationally. Modules 2 through 5 carry the substantive content:
- Module 2: Summaries and overviews across quality, nonclinical, and clinical domains
- Module 3: Full CMC documentation, including manufacturing processes, specifications, and stability data at commercial scale
- Module 4: Complete nonclinical study reports covering pharmacology, pharmacokinetics, and toxicology
- Module 5: All clinical study reports, including Phase I, II, and III data, along with post-marketing experience if available
The FDA’s standard review timeline is 10 months from filing acceptance (the PDUFA date). Priority Review, available for drugs addressing unmet medical needs, compresses that to 6 months. Rolling submission, where completed NDA sections are submitted before the full package is ready, can reduce the total timeline if your CMC documentation is ready early.
IND vs NDA: Key Differences Side by Side
| Criteria | IND | NDA |
|---|---|---|
| Purpose | Authorises clinical investigation | Authorises commercial marketing |
| Filing Stage | Pre-Phase I (before first-in-human) | Post-Phase III completion |
| Key Components | Preclinical data, early CMC, clinical protocol | Full clinical package, commercial CMC, labelling |
| FDA Review Period | 30-day hold window | 10 months standard; 6 months priority |
| Outcome of Approval | Permission to conduct trials | Permission to sell in the US market |
| Regulatory Code | 21 CFR Part 312 | 21 CFR Part 314 |
The CMC gap between IND and NDA is where programmes most often underestimate their workload. IND CMC requirements are deliberately limited: the FDA needs enough information to confirm the investigational product is safe to administer, not that it can be manufactured at commercial scale. NDA Module 3, by contrast, demands full process validation, commercial-scale batch data, and a complete stability programme. Sponsors who don’t begin building toward NDA-level CMC documentation during Phase II regularly face 12 to 18 months of manufacturing remediation before they can file.
The IND-to-NDA Transition in Practice
The transition from IND to NDA is not a single event. It’s a progressive accumulation of clinical, manufacturing, and safety data across three trial phases. Phase I establishes safety and pharmacokinetics in a small cohort, typically 20 to 80 subjects. Phase II explores efficacy signals and dose-ranging in a larger group. Phase III delivers the statistically powered, controlled evidence the NDA requires to demonstrate substantial efficacy.
The End-of-Phase II meeting with FDA is the most strategically important interaction in this arc. It’s where the FDA confirms whether your proposed Phase III design will generate data sufficient to support an NDA, and where CMC expectations for commercial manufacturing are first discussed in depth. Sponsors who skip or underprepare for this meeting often discover late in Phase III that their trial design has a gap the FDA won’t overlook.
IND safety reporting obligations continue throughout this entire period. Serious unexpected adverse reactions require 15-day expedited reports. Annual progress reports update the FDA on all ongoing IND activity. These aren’t administrative formalities. They build the safety database that Module 5 of your NDA will draw from directly.
Can you access expedited pathways? If your compound addresses a serious condition with unmet need, Breakthrough Therapy designation, Fast Track designation, or Accelerated Approval may apply. Each changes the FDA interaction cadence during the IND phase and can materially affect NDA review timelines. Assess your eligibility early, not after Phase III is complete.
IND and NDA vs EMA Equivalents
European operators often ask whether FDA logic maps to EMA processes. The functional parallels are clear, though the legal frameworks are distinct.
The EMA’s Clinical Trial Authorisation (CTA) is the IND equivalent. It permits clinical investigation within EU member states and requires a similar package of preclinical safety data, CMC information, and a clinical protocol. The EMA’s Marketing Authorisation Application (MAA) is the NDA equivalent, requiring full clinical evidence and commercial-scale manufacturing documentation before granting EU-wide approval.
Post-Brexit, UK sponsors must file separately with the MHRA under UK CTA and UK Marketing Authorisation frameworks. These broadly mirror EMA processes but are now legally distinct. If you’re designing a global development programme, building your data package to satisfy both FDA and EMA requirements from the outset is more efficient than retrofitting after a US-only NDA is filed.
Common Reasons Submissions Fail
IND clinical holds most commonly result from three causes: inadequate preclinical toxicology data, poorly justified starting doses, or insufficient CMC information to confirm product quality and consistency. The pre-IND meeting exists precisely to surface these gaps before submission, not after the 30-day clock has started.
NDA Complete Response Letters (CRLs), which the FDA issues when an application can’t be approved as filed, most frequently cite CMC deficiencies, clinical data gaps, or failure to address prior FDA feedback from End-of-Phase meetings. The pattern is consistent: sponsors who treat FDA interactions as checkboxes rather than genuine scientific exchanges tend to encounter the most expensive surprises at the NDA stage.
The single most effective risk-reduction strategy across both application types is consistent FDA engagement. Pre-IND meetings, End-of-Phase II meetings, and Pre-NDA meetings are not optional courtesies. They are the mechanism by which you confirm that your data package will meet the standard before you spend the time and capital to generate it.
What This Means for Your Programme Right Now
The IND and NDA define the structural boundaries of your entire development timeline. Where your programme sits on the IND-to-NDA arc determines what data you need next, what manufacturing investments to prioritise, and which FDA interactions to schedule. Treating them as separate bureaucratic milestones rather than two points on a connected journey is the most common strategic error in early-stage drug development.
If you’re preparing an IND, review the 21 CFR Part 312 checklist and request a pre-IND meeting using Form FDA 5018 before finalising your submission package. If you’re approaching End-of-Phase II, benchmark your CMC documentation against NDA Module 3 requirements now. The gap between where your manufacturing programme is and where it needs to be for NDA filing is almost always larger than it looks from Phase I.
For European operators building global programmes, map your FDA IND and NDA milestones against EMA CTA and MAA requirements from day one. The data packages overlap substantially. Building once for both regulators is the more capital-efficient path, and it positions your asset for commercial approval in the two largest pharmaceutical markets simultaneously.
Key Regulatory Terms
- IND (Investigational New Drug application): The FDA submission under 21 CFR Part 312 that authorises clinical trials in the United States.
- NDA (New Drug Application): The FDA submission under 21 CFR Part 314 requesting permission to market a new drug commercially.
- CMC (Chemistry, Manufacturing, and Controls): The section of both IND and NDA submissions covering drug substance and drug product manufacturing, specifications, and quality controls.
- CTD (Common Technical Document): The internationally harmonised five-module format used for NDA and MAA submissions.
- PDUFA date: The FDA’s target action date for NDA review, set under the Prescription Drug User Fee Act.
- Clinical hold: An FDA order halting or suspending a clinical trial due to safety or regulatory concerns identified during IND review.
- Rolling submission: An NDA filing approach allowing completed sections to be submitted before the full package is ready, compressing total review time.
- CRL (Complete Response Letter): An FDA communication indicating an NDA cannot be approved in its current form, citing specific deficiencies requiring resolution.
